Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Coloplast A

Healthcare US CLPBY

5.71USD
-0.04(0.70%)

Last update at 2026-06-22T17:46:00Z

Day Range

5.665.73
LowHigh

52 Week Range

6.5110.87
LowHigh

Fundamentals

  • Previous Close 5.75
  • Market Cap15542.51M
  • Volume12845
  • P/E Ratio24.32
  • Dividend Yield5.25%
  • EBITDA8584.00M
  • Revenue TTM27891.00M
  • Revenue Per Share TTM12.37
  • Gross Profit TTM 18930.00M
  • Diluted EPS TTM0.28

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Type yearly yearly yearly yearly yearly
Date 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Income before tax 5799.00M 6395.00M 6025.00M 6127.00M 6233.00M
Minority interest - - - - -
Net income 3425.00M 5052.00M 4783.00M 4706.00M 4825.00M
Selling general administrative - 1244.00M 1115.00M 1005.00M 762.00M
Selling and marketing expenses - 8825.00M 7518.00M 6797.00M 5485.00M
Gross profit 17082.00M 18269.00M 16328.00M 15529.00M 13313.00M
Reconciled depreciation - 1290.00M 1069.00M 930.00M 792.00M
Ebit 6577.00M 7190.00M 6661.00M 6439.00M 6355.00M
Ebitda 7852.00M 8480.00M 7730.00M 7864.00M 7233.00M
Depreciation and amortization 1275.00M 1290.00M 1069.00M 1425.00M 878.00M
Non operating income net other - - - - -
Operating income 7139.00M 7320.00M 6771.00M 6439.00M 6355.00M
Other operating expenses 19116.00M 19710.00M 17655.00M 15669.00M 13071.00M
Interest expense 777.06M 882.00M 638.00M 172.00M 25.00M
Tax provision - 1343.00M 1242.00M 1421.00M 1408.00M
Interest income - 155.00M 111.00M 12.00M 11.00M
Net interest income - -725.00000M -604.00000M -224.00000M -45.00000M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 2375.00M 1343.00M 1242.00M 1421.00M 1408.00M
Total revenue 26254.00M 27030.00M 24500.00M 22579.00M 19426.00M
Total operating expenses 9944.00M 10949.00M 9483.00M 8619.00M 6958.00M
Cost of revenue 9172.00M 8761.00M 8172.00M 7050.00M 6113.00M
Total other income expense net -1339.00000M -925.00000M -746.00000M -312.00000M -122.00000M
Discontinued operations - - - - -
Net income from continuing ops - 5052.00M 4783.00M 4706.00M 4825.00M
Net income applicable to common shares - - - 4706.00M 4825.00M
Preferred stock and other adjustments - - - - -
Breakdown 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Type yearly yearly yearly yearly yearly
Date 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Total assets 48463.00M 48073.00M 48159.00M 34956.00M 15841.00M
Intangible assets 10503.00M 10957.00M 11281.00M 8469.00M 1623.00M
Earning assets - - - - -
Other current assets 412.12M 5984.00M - - 3892.00M
Total liab 32309.00M 30131.00M 30860.00M 26664.00M 7673.00M
Total stockholder equity 16154.00M 17942.00M 17299.00M 8292.00M 8168.00M
Deferred long term liab - - - - -
Other current liab 2596.00M 2481.00M 1.00M 4241.00M 8.00M
Common stock 228.45M 228.00M 228.00M 216.00M 216.00M
Capital stock - - 228.00M 216.00M 216.00M
Retained earnings 17710.00M 15391.00M 14632.00M 5386.00M 5406.00M
Other liab - - - 2473.00M 910.00M
Good will 19367.00M 19375.00M 19974.00M 11808.00M 2028.00M
Other assets - - - 1891.00M 1655.00M
Cash 948.88M 788.00M 911.00M 414.00M 448.00M
Cash and equivalents - - - - -
Total current liabilities 6518.00M 10204.00M 16311.00M 7336.00M 6314.00M
Current deferred revenue - - 7671.00M - 2933.00M
Net debt 21735.12M 21841.00M 18656.00M 18294.00M 2338.00M
Short term debt 2595.00M 5338.00M 7345.00M 1853.00M 2337.00M
Short long term debt - - 7115.00M 1644.00M 2160.00M
Short long term debt total 22684.00M 22629.00M 19567.00M 18708.00M 2786.00M
Other stockholder equity - 2323.00M 2439.00M 2690.00M 2546.00M
Property plant equipment - - - 4133.00M 3584.00M
Total current assets 10474.00M 10444.00M 9937.00M 8772.00M 6994.00M
Long term investments - - - - -
Net tangible assets - - - -11817.00000M 4601.00M
Short term investments - - - 219.00M 226.00M
Net receivables 5186.00M - 4315.00M 4659.00M 3720.00M
Long term debt - - 11558.00M 16359.00M -
Inventory 3927.00M 3672.00M 3522.00M 3187.00M 2428.00M
Accounts payable 1327.00M 1519.00M 1294.00M 1242.00M 1036.00M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -1785.00000M - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 316.61M 102.00M 104.00M 250.00M 252.00M
Deferred long term asset charges - - - - -
Non current assets total 37989.00M 37629.00M 38222.00M 26184.00M 8847.00M
Capital lease obligations - - 894.00M 705.00M 626.00M
Long term debt total - - - - -
Breakdown 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Type yearly yearly yearly yearly yearly
Date 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Investments - -1336.00000M -8957.00000M -2.00000M 16.00M
Change to liabilities - - - 337.00M 224.00M
Total cashflows from investing activities -1178.00000M -1336.00000M - -11759.00000M -2011.00000M
Net borrowings - 2970.00M - 10730.00M 848.00M
Total cash from financing activities -4886.00000M -1518.00000M 5265.00M 6591.00M -3176.00000M
Change to operating activities - - - -295.00000M 97.00M
Net income 3425.00M 5052.00M 6771.00M 6439.00M 6155.00M
Change in cash 197.93M -123.00000M 497.00M -34.00000M 125.00M
Begin period cash flow 750.95M 911.00M 414.00M 448.00M 323.00M
End period cash flow 948.88M 788.00M 911.00M 414.00M 448.00M
Total cash from operating activities 6259.00M 2766.00M 4226.00M 5099.00M 5290.00M
Issuance of capital stock - 500.00M 9134.00M - 306.00M
Depreciation 1275.00M 1290.00M 1069.00M 930.00M 792.00M
Other cashflows from investing activities 0.45M -165.00000M - - -
Dividends paid 4670.00M 4720.00M 4247.00M 4041.00M 3830.00M
Change to inventory -415.00000M -290.00000M -474.00000M -540.00000M -161.00000M
Change to account receivables -34.00000M -506.00000M - -351.00000M -235.00000M
Sale purchase of stock - - 0.00000M -619.00000M -500.00000M
Other cashflows from financing activities -264.97800M -268.00000M 378.00M 16649.00M 848.00M
Change to netincome - - - 312.00M -252.00000M
Capital expenditures 1230.00M 1166.00M 1241.00M 1135.00M 1966.00M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -739.00000M -1032.00000M -893.00000M -849.00000M -75.00000M
Stock based compensation - - - - -
Other non cash items 2298.00M -2544.00000M -2721.00000M -1421.00000M -1582.00000M
Free cash flow 5029.00M 1600.00M 2985.00M 3964.00M 3324.00M

Peer Comparison

Sector: Healthcare Industry: Medical Instruments & Supplies

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CLPBY
Coloplast A		 -0.04 0.70% 5.71 24.32 17.18 0.56 7.06 4.48 14.95
ISRG
Intuitive Surgical Inc		 -5.27 1.30% 401.51 73.05 61.73 19.15 10.25 18.41 59.92
ESLOF
EssilorLuxottica Société anonyme		 -13.86 6.73% 192.00 44.84 27.62 4.07 2.49 3.71 16.04
ESLOY
Essilor International SA		 -5.43 5.33% 96.49 41.68 27.25 3.94 2.45 3.71 16.04
BDX
Becton Dickinson and Company		 -2.45 1.70% 141.53 25.56 12.48 2.59 1.76 2.89 12.55

Reports Covered

Stock Research & News

View All

Profile

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Dressings and Biologics segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; Peristeen Plus, a transanal irrigation system; and Peristeen Light, a low-volume transanal irrigation. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as erectile dysfunction, urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.

Coloplast A

Holtedam 1-3, Humlebæk, Denmark, 3050

Key Executives

Name Title Year Born
Mr. Kristian Villumsen Pres & CEO 1970
Mr. Anders Lonning-Skovgaard Exec. VP & CFO 1972
Mr. Allan Rasmussen Exec. VP of Global Operations 1967
Mr. Nicolai Buhl Andersen Exec. VP of Innovation 1969
Mr. Paul Marcun Exec. VP of Growth 1967
Mr. Thomas Barfod Sr. Controller & Employees Representative Director 1970
Ellen Bjurgert VP of Investor Relations NA
Dennis Kaysen Director of Corp. Communications NA
Dorthe Ronnau Sr. VP of People & Culture 1966
Mr. Alain Morvan Sr. VP of Sales Europe NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.